

Anti-Trastuzumab Monoclonal Antibody

Catalog #: ASPF20

Product Details

Product Description:	This human anti-idiotypic antibody is engineered to specifically recognize the antigen-binding region of trastuzumab without binding to HER2 directly. Affinity-purified, azide-free, and >95% monomeric by SEC, it's a valuable tool for streamlining regulatory bioanalysis of HER2-targeted therapeutics, including PK/PD bridging ELISA, ADA detection, and biosimilar development.
Host Species:	Human
Target:	Trastuzumab
Target Species:	Human
Specificity:	This antibody recognizes the idiotype of trastuzumab, effectively mimicking HER2 epitopes.
Species Reactivity:	Human
Immunogen:	Trastuzumab F(ab') ₂ fragments.
Clonality:	Monoclonal
Purification:	The antibody was purified by affinity chromatography.
Purity:	>95% as determined by SDS-PAGE
Aggregation:	<5% as determined by SEC

Formulation Information

Sterility:	0.2 µM filtered
Preservative:	BSA and Azide free.
Stabilizer:	None

Applications

Applications:	Blocking
Note:	Optimal dilutions/concentrations should be determined by the end user.

Storage & Handling

Shipping:	Shipped at 4°C.
Storage:	This antibody can be stored at 2°C-8°C for one month. Upon delivery aliquot. For longer storage, store at -20°C. Avoid repeated freeze-thaw cycles.

Target Details

Protein Name:	Trastuzumab
Introduction:	Trastuzumab is a monoclonal antibody drug that targets HER2 (human epidermal growth factor receptor 2). It is primarily used to treat HER2-positive breast and gastric cancers. Trastuzumab works by binding to the HER2 receptor on cancer cells, inhibiting its signaling pathways, and recruiting immune cells to attack the tumor, leading to therapeutic effects.
Alternative Names:	human HER2 mimetic
Related Disease:	HER2-positive Breast Cancer
Function:	A monoclonal antibody used to treat certain breast cancers by targeting ERBB2.